查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1085009

性健康的全球市场:各产品类型，性别，各流通管道，各地区-规模，占有率，展望，机会分析(2022年～2028年)

Sexual Health Market, by Product Type, by Gender, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
出版日期: | 出版商: Coherent Market Insights | 英文 167 Pages | 商品交期: 2-3个工作天内

价格
简介目录

性障碍的发生率及盛行率增加，预计是增大市场成长的主要原因。还有法规当局对性健康相关核准数量增加，也预期促进市场成长。

本报告提供全球性健康市场的相关调查，市场展望，市场动态，市场分析，竞争情形等全面性资讯。

目录

第1章 调查目的、前提条件

第2章 市场概要

  • 报告的说明
  • 摘要整理
    • 市场明细:各产品类型
    • 市场明细:性别
    • 市场明细:各流通管道
    • 市场明细:各地区
  • Coherent Opportunity Map(COM)

第3章 市场动态，法规，及趋势分析

  • 市场动态
  • 促进因素
  • 阻碍因素
  • 市场机会
  • 影响分析
  • 市场趋势
  • 主要的开发
  • 技术的进步
  • 合併和收购
  • 产业趋势
  • 法规情境
  • 波特的5个力量
  • PEST分析

第4章 全球性健康市场:各产品类型(100万美元)(2017年～2028年)

  • 简介
  • 勃起功能障碍治疗药
  • 性别认同障碍治疗药
  • 低性慾障碍治疗药
  • 早洩治疗药
  • 其他

第5章 全球性健康市场:性别(100万美元)(2017年～2028年)

  • 简介
  • 男性
  • 女性

第6章 全球性健康市场:各流通管道(100万美元)(2017年～2028年)

  • 简介
  • 医院药局
  • 零售药局
  • 线上药局

第7章 全球性健康市场:各地区(100万美元)(2017年～2028年)

  • 简介
  • 市场占有率分析(%)(2022年～2028年)
  • 与前一年同期比较成长分析(2017年～2028年)
  • 市场区隔趋势
  • 北美
  • 美国
  • 加拿大
  • 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他的欧洲
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 东南亚国协
  • 澳洲
  • 韩国
  • 其他的亚太地区
  • 南美
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他的南美
  • 中东
  • GCC各国
  • 以色列
  • 其他的中东
  • 非洲
  • 北非
  • 中非
  • 南非

第8章 竞争情形

  • 热图分析
  • 企业简介
    • Teva Pharmaceutical Industries Ltd.
    • Meda Pharmaceuticals, Inc.
    • Eli Lilly & Company
    • Bayer AG
    • Vivus, Inc.
    • Zydus Pharmaceuticals
    • IVFTECH APS
    • Merck & Co.
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd
    • Novartis International AG
    • Mylan Pharmaceuticals Inc.
    • AstraZeneca

第9章 Section

简介目录
Product Code: CMI3364

Sexual health is an important part of a person's physical and mental health. Sexual health leads to the healthy sexual life without any sexual dysfunctions, and preventive measures to avoid sexually transmitted infections. The adult population largely suffers from one or more sexual disorders such as dyspareunia, erectile dysfunctions, hypoactive sexual desire disorder, premature (early) ejaculation, and others. According to National Center for Biotechnology Information 2016, sexual dysfunction is highly prevalent, and affects around 43% of women and 31% of men, globally. Currently, various treatment options such as medication, mechanical aids, sexual therapies, and others are available for treating such sexual dysfunctions and to improve sexual health of the person.

Market Dynamics

Increasing incidence and prevalence of sexual disorders is a major factor augmenting growth of the market. Some of the major factors which cause sexual dysfunction are aging population, stressful and unhealthy lifestyle, and other psychological parameters. According to a study published in the National Center for Biotechnology Information in April 2016, hypoactive sexual desire disorder (HSDD) is present in around 8.9% and 12.3% women in the age group of 18 - 44 years and 45 - 64 years, respectively.

Moreover, robust product development activities by major key players is engaged in the introduction of innovative and highly effective drug treatment for improving sexual health. For instance, in June 2019, AMAG Pharmaceuticals received the U.S. FDA approval for Vyleesi (bremelanotide) for treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Thus, increasing approvals by regulatory authorities are expected to drive the growth of the sexual health market.

Key features of the study:

  • This report provides in-depth analysis of the global sexual health market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2022-2028), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles leading players in the global sexual health market based on the following parameters - company overview, financial performance, technology portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Teva Pharmaceutical Industries Ltd., Meda Pharmaceuticals, Inc., Eli Lilly & Company, Bayer AG, Vivus, Inc., Zydus Pharmaceuticals, IVFTECH APS, Merck & Co., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Novartis International AG, Mylan Pharmaceuticals Inc., and AstraZeneca
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future technology launches, government initiatives, technological upgradation, market expansion, and marketing tactics
  • The global sexual health market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers in the sexual health market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Sexual Health Market, By Product Type:
  • Erectile Dysfunction Drugs
  • Gender Dysphoria Drugs
  • Hypoactive Sexual Desire Disorder Drugs
  • Premature Ejaculation Drugs
  • Others
  • Global Sexual Health Market, By Gender:
  • Male
  • Female
  • Global Sexual Health Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Sexual Health Market, By Region:
  • North America
    • By Product Type:
  • Erectile Dysfunction Drugs
  • Gender Dysphoria Drugs
  • Hypoactive Sexual Desire Disorder Drugs
  • Premature Ejaculation Drugs
  • Others
    • By Gender:
  • Male
  • Female
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
    • By Country:
  • U.S.
  • Canada
  • Europe
    • By Product Type:
  • Erectile Dysfunction Drugs
  • Gender Dysphoria Drugs
  • Hypoactive Sexual Desire Disorder Drugs
  • Premature Ejaculation Drugs
  • Others
    • By Gender:
  • Male
  • Female
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
    • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Product Type:
  • Erectile Dysfunction Drugs
  • Gender Dysphoria Drugs
  • Hypoactive Sexual Desire Disorder Drugs
  • Premature Ejaculation Drugs
  • Others
    • By Gender:
  • Male
  • Female
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
    • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • By Product Type:
  • Erectile Dysfunction Drugs
  • Gender Dysphoria Drugs
  • Hypoactive Sexual Desire Disorder Drugs
  • Premature Ejaculation Drugs
  • Others
    • By Gender:
  • Male
  • Female
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • By Product Type:
  • Erectile Dysfunction Drugs
  • Gender Dysphoria Drugs
  • Hypoactive Sexual Desire Disorder Drugs
  • Premature Ejaculation Drugs
  • Others
    • By Gender:
  • Male
  • Female
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Product Type:
  • Erectile Dysfunction Drugs
  • Gender Dysphoria Drugs
  • Hypoactive Sexual Desire Disorder Drugs
  • Premature Ejaculation Drugs
  • Others
    • By Gender:
  • Male
  • Female
    • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
  • Company Profiles
    • Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Technology Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
    • Meda Pharmaceuticals, Inc.
    • Eli Lilly & Company
    • Bayer AG
    • Vivus, Inc.
    • Zydus Pharmaceuticals
    • IVFTECH APS
    • Merck & Co.
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd
    • Novartis International AG
    • Mylan Pharmaceuticals Inc.
    • AstraZeneca

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description

1. Market Definition and Scope

  • Executive Summary

1. Market Snippet, By Product Type

2. Market Snippet, By Gender

3. Market Snippet, By Distribution Channel

4. Market Snippet, By Region

  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics

1. Drivers

2. Restraints

3. Market Opportunities

  • Impact Analysis
  • Market Trends
  • Key Developments
  • Technology Advancements
  • Merger and Acquisition
  • Regulatory Scenario
  • PORTER'S Five Forces
  • PEST Analysis

4. Global Sexual Health Market, By Product Type, 2017 - 2028, (US$ Million)

  • Introduction

1. Market Share Analysis, 2022 and 2028 (%)

2. Y-o-Y Growth Analysis, 2017 - 2028

3. Segment Trends

  • Erectile Dysfunction Drugs

1. Introduction

2. Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

  • Gender Dysphoria Drugs

1. Introduction

2. Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

  • Hypoactive Sexual Desire Disorder Drugs

1. Introduction

2. Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

  • Premature Ejaculation Drugs

1. Introduction

2. Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

  • Others

1. Introduction

2. Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

5. Global Sexual Health Market, By Gender, 2017 - 2028, (US$ Million)

  • Introduction

1. Market Share Analysis, 2022 and 2028 (%)

2. Y-o-Y Growth Analysis, 2017 - 2028

3. Segment Trends

  • Male

1. Introduction

2. Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

  • Female

1. Introduction

2. Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Sexual Health Market, By Distribution Channel, 2017 - 2028, (US$ Million)

  • Introduction

1. Market Share Analysis, 2022 and 2028 (%)

2. Y-o-Y Growth Analysis, 2017 - 2028

3. Segment Trends

  • Hospital Pharmacy

1. Introduction

2. Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

  • Retail Pharmacy

1. Introduction

2. Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

  • Online Pharmacy

1. Introduction

2. Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Sexual Health Market, By Region, 2017 - 2028, (US$ Million)

  • Introduction

1. Market Share Analysis, By Region, 2022 and 2028 (%)

2. Y-o-Y Growth Analysis, By Region, 2017 - 2028

3. Regional Trends

  • North America

1. Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million)

2. Market Size and Forecast, By Gender, 2017 - 2028, (US$ Million)

3. Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)

4. Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)

    • U.S.
    • Canada
  • Europe

1. Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million)

2. Market Size and Forecast, By Gender, 2017 - 2028, (US$ Million)

3. Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)

4. Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)

    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific

1. Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million)

2. Market Size and Forecast, By Gender, 2017 - 2028, (US$ Million)

3. Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)

4. Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)

    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America

1. Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million)

2. Market Size and Forecast, By Gender, 2017 - 2028, (US$ Million)

3. Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)

4. Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)

    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East

1. Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million)

2. Market Size and Forecast, By Gender, 2017 - 2028, (US$ Million)

3. Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)

4. Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)

    • GCC
    • Israel
    • Rest of Middle East
  • Africa

1. Market Size and Forecast, By Product Type, 2017 - 2028, (US$ Million)

2. Market Size and Forecast, By Gender, 2017 - 2028, (US$ Million)

3. Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)

4. Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million)

    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles

1. Teva Pharmaceutical Industries Ltd.

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

2. Meda Pharmaceuticals, Inc.

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

3. Eli Lilly & Company

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

4. Bayer AG

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

5. Vivus, Inc.

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

6. Zydus Pharmaceuticals

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

7. IVFTECH APS

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

8. Merck & Co.

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

9. Pfizer Inc.

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

10. Sun Pharmaceutical Industries Ltd

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

11. Novartis International AG

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

12. Mylan Pharmaceuticals Inc.

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

13. AstraZeneca

    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact